Harrow Inc (HROW)
45.78
-0.09
(-0.20%)
USD |
NASDAQ |
Nov 05, 16:00
45.78
0.00 (0.00%)
After-Hours: 20:00
Harrow Research and Development Expense (Annual): 6.652M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 6.652M |
| December 31, 2022 | 3.05M |
| December 31, 2021 | 11.08M |
| December 31, 2020 | 2.413M |
| December 31, 2019 | 2.083M |
| December 31, 2018 | 0.825M |
| December 31, 2017 | 0.413M |
| December 31, 2016 | 0.739M |
| December 31, 2015 | 0.332M |
| Date | Value |
|---|---|
| December 31, 2014 | 0.237M |
| December 31, 2013 | 1.616M |
| December 31, 2012 | 1.298M |
| December 31, 2011 | 0.1116M |
| December 31, 2010 | 0.1946M |
| December 31, 2009 | 2.966M |
| December 31, 2008 | 1.991M |
| December 31, 2007 | 1.833M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.083M
Minimum
2019
11.08M
Maximum
2021
5.056M
Average
3.05M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Omeros Corp | 114.87M |
| Amphastar Pharmaceuticals Inc | 73.74M |
| PetIQ Inc | -- |
| Alector Inc | 192.12M |
| Outset Medical Inc | 57.31M |